A recent phase 3 trial showed that combining nivolumab with AVD chemotherapy improves 2-year progression-free survival while also offering a superior safety profile compared with a brentuximab vedotin...
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
In this video, Hector R. Villarraga, MD, discusses the long-term incidence of heart failure in patients with breast cancer or lymphoma treated with anthracycline therapy and the clinical impact of his...
In this video, Mark Roschewski, MD, discusses the results of his team’s study of the use of PET/CT scans to assess remission status in patients with aggressive B-cell lymphoma. Dr Roschewski presented these...
In this video, Mark Roschewski, MD, discusses the key points from his team’s research that investigated the value of circulating tumor DNA when treating patients with diffuse large B-cell lymphoma. The...
In this video, Paolo Strati, MD, discusses chemotherapy-free approaches in the treatment of patients with indolent b-cell lymphoma, including early trials that are underway on the combination of...
In this video, Mark Roschewski, MD, discusses the key established principles in circulating tumor DNA (ctDNA) in lymphoma, including using ctDNA in prognosis, as a measure of tumor burden, and acting on...
